[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sars-cov-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sars-cov-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100425068","phase-2-imaging-immune-activation-in-covid-19-100425068",false,"NCT04815096","Imaging Immune Activation in COVID-19","Inclusion Criteria:\n\n* Age \\>18 years\n* Ability to read and understand written informed consent document\n* Have a recent diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples.\n* \\> 14 days since onset of COVID-19 symptoms (or if no symptoms, from time of initial nucleic acid based diagnostic test).\n* Laboratory evaluations obtained within 60 days prior to entry.\n\n  * Platelet count ≥75,000\u002Fmm3\n  * ANC \\>1000\u002Fmm3\n  * Aspartate aminotransferase (AST) \\\u003C3 x ULN\n  * Alanine aminotransferase (ALT) \\\u003C3 x ULN\n  * Calculated creatinine clearance (CrCl) ≥60 mL\u002Fmin as estimated by the Cockcroft-\n  * Gault equation\n\nExclusion Criteria:\n\n* Any medical condition that would compromise the imaging acquisition, in the opinion of the investigator\n* Participants who are pregnant (female participants of childbearing age will be tested prior to injection of imaging agent at entry visit\u002Finitial visit - positive test will exclude from further participation in the study)\n* Participants who are breastfeeding\n* Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy) must have a negative urine or serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL performed within 24 hours prior to PET imaging. Females of reproductive potential will need to be on 2 forms of birth control (excluding withdrawal or timing methods).\n* Participants who have had prior allogeneic stem cell or solid organ transplant.\n* Screening absolute neutrophil count \\\u003C1,000 cells\u002Fmm3, platelet count \\\u003C75,000 cells\u002Fmm3, hemoglobin \\\u003C 8 mg\u002FdL, estimated creatinine clearance \\\u003C60 mL\u002Fminute, aspartate aminotransferase \\>3 x ULN, alanine aminotransferase \\>3 x ULN.\n* Known SARS-CoV-2 shedding within 5 days of PET imaging.\n* Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry\n* Active systemic autoimmune diseases not related to COVID-19.\n* COVID-19 vaccine prior to the first PET imaging session. Participants may receive COVID-19 vaccination after the first PET imaging session and the optional second PET scan, with the scan being performed at least 2 weeks following the most recent vaccine dose.\n* Prior PET scan or therapeutic radiation within 1 year of study enrollment.","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \\[18F\\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.",[25,26],"Covid19","SARS-CoV Infection",[28,29],"PET-CT Imaging","[18F]F-AraG","RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2021-04-15",{"date":38,"type":19},"2028-10-01",{"name":40,"class":41},"CellSight Technologies, Inc.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100507394","phase-2-mitoquinonemitoquinol-mesylate-as-oral-and-safe-postexposure-prophylaxis-for-covid-19-100507394","NCT05886816","Mitoquinone\u002FMitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19","Inclusion Criteria:\n\nAge 18-65 years old Asymptomatic (no symptoms of viral infection) on study entry High risk exposure without use of masks to confirmed case of COVID-19 Members in a household one of which is a confirmed case of COVID-19 Negative baseline SARS-COV-2 diagnostic test\n\nExclusion Criteria:\n\n* Women with variations in physiological functions due to hormones that may effect immune function and (transgender, pregnant, breastfeeding)\n* Specific significant clinical diseases \\[cardiovascular disease (such as coronary artery\u002Fvascular disease), heart disease (such as congestive heart failure, cardiomyopathy, atrial fibrillation), lung disease (such as chronic obstructive pulmonary disease, asthma, bronchiectasis, pulmonary fibrosis, pleural effusions), kidney disease (glomerular filtration rate or GFR less than 60 ml\u002Fmin\u002F1.73 m2), liver disease (such as cirrhosis, hepatitis), major immunosuppression (such as history of transplantation, uncontrolled HIV infection, cancer on active chemotherapy\\] based on history. Participants with well controlled HIV (CD4 count \\> 500 cells\u002Fmm\\^3 and HIV viral load \\\u003C 50 copies\u002Fml) and people with remote history of cancer not on active treatment will be allowed to participate.\n* History of known gastrointestinal disease (such as gastroparesis) that may predispose patients to nausea\n* History of auto-immune diseases\n* Chronic viral hepatitis\n* Use of systemic immunomodulatory medications (e.g. steroids) within 4 weeks of enrollment\n* Any participant who has received any investigational drug within 30 days of dosing\n* History of underlying cardiac arrhythmia\n* History of severe recent cardiac or pulmonary event\n* A history of a hypersensitivity reaction to any components of the study drug or structurally similar compounds including Coenzyme Q10 and idebenone\n* Unable to swallow tablets\n* Use of any investigational products within 4 weeks of enrollment\n* Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.\n* Eligible for other FDA approved treatment for post-exposure prophylaxis against SARS-CoV-2\n* Use of Coenzyme Q10 or Vitamin E \\\u003C 120 days from enrollment",true,"65 Years",{"count":52,"type":19},112,[22],"Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone\u002Fmitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.",[26,56],"COVID-19",[26,56,58],"Post-exposure prophylaxis","2026-03-12",{"date":61,"type":34},"2026-03-16",{"date":63,"type":34},"2024-03-01",{"date":65,"type":19},"2026-07-31",{"name":67,"class":68},"University of Texas Southwestern Medical Center","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100416676","kidney-injury-in-times-of-covid-19-kidcov-100416676","NCT04705766","KIDney Injury in Times of COVID-19 (KIDCOV)","The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY","KIDCOV","Inclusion Criteria:\n\n* Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC\n* Age 18 years or older at enrollment\n* Race\u002Fethnicity, sex, age, and phone and\u002For home\u002Femail address provided\n\nExclusion Criteria:\n\n* Failure of a candidate participant to give written informed consent to comply with the study protocol\n* Hospitalization up to 4 weeks after SARS-CoV-2 test\n* History of kidney transplant\n* History of dialysis",{"count":78,"type":19},2000,"1 Year","OBSERVATIONAL","There is an unmet need to evaluate the impact of sub-clinical\u002Fmild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race\u002Fethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race\u002Fethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.",[26,25,83,84,85],"Corona Virus Infection","Acute Kidney Injury","Kidney Injury",[87,84,56,88,89,90,91,92,93,85],"SARS-CoV-2","Coronaviurs","COVID-19 Infection","SARS-CoV-2 infection","Coronavirus infection","COVID-19 and Acute Kidney Injury","SARS-CoV-2 & Kidney Injury Risk Factors","2025-07-24",{"date":96,"type":34},"2025-07-28",{"date":98,"type":34},"2021-03-01",{"date":100,"type":19},"2027-03",{"name":102,"class":68},"University of California, San Francisco",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100406980","prevalence-and-outcome-of-sars-cov-2-infection--covid-19-in-transplant-recipients-the-covitra-study-100406980","NCT04579471","Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study","Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study","COVITRA","Inclusion Criteria:\n\n* all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent\n\nExclusion Criteria:\n\n* age under 18 years","90 Years",{"count":78,"type":19},"This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.",[25,26,116],"Transplantation Infection",[118,26,119],"covid19","transplantation","2024-07-02",{"date":122,"type":34},"2024-07-03",{"date":124,"type":34},"2020-07-01",{"date":126,"type":19},"2025-12-31",{"name":128,"class":68},"Universitaire Ziekenhuizen KU Leuven"]